Tivic Health Systems Inc. (NASDAQ:TIVC) shares jumped 24.10% to $1.39 in after-hours trading after the San Antonio-based company announced a full corporate rebrand to Valion Bio, Inc., with its ticker shifting to VBIO at market open on April 28.
Strategic Transformation Behind The Rebrand
The rebrand caps a fundamental strategic pivot, exiting consumer medical devices and repositioning around Entolimod™, a TLR5 agonist developed as a medical countermeasure for acute radiation syndrome, with Food and Drug Administration Fast Track and Orphan Drug designations. The asset is advancing under the FDA’s Animal Rule pathway, which permits approval based on animal efficacy data when human trials are not feasible or ethical.
Valion Bio is actively engaging the Biomedical Advanced Research and Development Authority (BARDA), the Defense Threat Reduction Agency (DTRA), and the National Institute of Allergy and Infectious Diseases (NIAID) regarding Entolimod’s inclusion in the U.S. Strategic National Stockpile— a procurement contract the company says could represent a non-dilutive, nine-figure revenue event.
Trading Metrics, Technical Analysis
Tivic Health, a late-stage immunotherapeutics company, has a market capitalization of $3.22 million, with a 52-week high of $7.74 and a 52-week low of $0.72.
The Relative Strength Index (RSI) of TIVC stands at 56.26.
The small-cap stock has dropped 84.09% over the past 12 months.
Currently, the stock is positioned at about 5.7% above its 52-week low, meaning it is still trading near the lower end of its yearly range.
Price Action: Tivic closed the regular session down 1.75% at $1.12, according to Benzinga Pro.
Benzinga's Edge Stock Rankings indicate that TIVC is experiencing long-term consolidation along with medium and short-term upward movement.
Photo Courtesy: abunuh051992 on Shutterstock.com
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Login to comment